Rs 10k cr 'Biopharma Shakti' an investment in India’s health, innovation future: Industry

Why Budget 2026 Matters for Indian Healthcare %Union Budget 2026

India’s Union Budget 2026 is not merely an annual fiscal exercise; it is a directional signal for how the country envisions its healthcare system over the next decade. By crossing the psychological threshold of ₹1 lakh crore in health allocation and explicitly backing biotechnology, allied health workforce expansion, emergency care, and affordability of advanced therapies, […] The post Why Budget 2026 Matters for Indian Healthcare appeared first…

Budget backs long-term biopharma growth: EY

The Union Budget 2026 has signalled a sustained policy push for India's pharmaceutical and life sciences sector, with a strong emphasis on biopharma innovation, research infrastructure and affordability, even as direct tax incentives remain unchanged, noted EY's Budget sectoral alert.

Industry calls Union Budget 2026 a defining moment for India’s biopharma future

Industry stakeholders view the Union Budget 2026 as a pivotal inflection point in India’s life sciences journey. With the launch of the ₹10,000-crore Biopharma Shakti programme, expansion of clinical trial capacity, strengthening of regulatory institutions, and targeted patient access measures, stakeholders believe India is laying the groundwork to compete in high-value biologics, biosimilars, and advanced therapies. The emphasis on skills, scie…

Rs 10k cr 'Biopharma Shakti' an investment in India’s health, innovation future: Industry

New Delhi, Feb 1 (PTI) The government has made a decisive investment in the country’s health and innovation future by proposing an outlay of Rs 10,000 crore in the budget for the development of the biopharma sector over the next five years, according to the industry leaders. The Union Budget 2026-27 has also proposed setting up 1,000 clinical trial sites and strengthening the Central Drugs Standard Control Organisation. “By placing biopharma amo…